新型Midkine抑制剂诱导多发性髓瘤细胞周期停止和细胞亡
Kodcharat Cheevapruk1,2,3, Mikinori Ueno1,4, Prin Sungwan1,2
1Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Anticancer research
|February 29, 2024
概括
新型中基因抑制剂iMDK通过诱导细胞循环停止和亡,有效地减少多发性骨髓瘤 (MM) 细胞增殖. 这种化合物显示出作为这种血液性恶性瘤的潜在新治疗方法的希望.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 多发性骨髓瘤 (MM) 是一种流行的血液性恶性瘤,具有有限的治愈治疗选择.
- 新的治疗策略对于改善MM患者的治疗结果至关重要.
研究的目的:
- 为了研究中抑制剂iMDK在多发性骨髓瘤细胞系上的抗癌作用.
- 阐明IMDK抗髓瘤活性背后的分子机制.
主要方法:
- 使用MTT试验评估了抗增殖活性.
- 通过流式细胞计量分析了细胞周期进展和细胞亡.
- 西方涂抹被用来检查关键的细胞周期和细胞亡调节蛋白质.
主要成果:
- iMDK证明了剂量和时间依赖的MM细胞增殖抑制.
- 治疗iMDK诱导的G2/M阶段细胞周期停止,与减少Cdc20表达有关.
- 通过降低抗亡蛋白 (Bcl-2,Bcl-xL,Mcl-1,c-FLIP) 的调节和激活内在和外在的亡途径,iMDK引发了亡.
结论:
- 中基因抑制剂iMDK表现出显著的抗髓瘤活性.
- iMDK代表了治疗多发性骨髓瘤的潜在治疗候选者.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Negative Regulator Molecules
35.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K


